References
- van Roijen L, Koopmanschap MA, Rutten FF, van der Maas PJ. Indirect costs of disease; an international comparison. Health Policy 1995;33(1):15-29
- Valentini G, Black C. Systemic sclerosis. Best Pract Res Clin Rheumatol 2002;16(5):807-16
- Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69(10):1809-15
- Cervera R, Khamashta MA, Hughes GR. The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus 2009;18(10):869-74
- Macejová Z, Záriková M, Oetterová M. Systemic lupus erythematosus–disease impact on patients. Cent Eur J Public Health 2013;21(3):171-3
- Nunes H, Bouvry D, Soler P, Valeyre D. Sarcoidosis. Orphanet J Rare Dis 2007;2:46
- ZUS Statistical Portal. Available from: www.psz.zus.pl/ [Last accessed 03 November 2014]
- Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. Pharmacoeconomics 2014;32(4):335-44
- Central Statistical Office of Poland. Available from: http://stat.gov.pl/en/ [Last accessed 03 November 2014]
- National Bank of Poland. Available from http://nbp.pl/homen.aspx?f=/srodeken.htm [Last accessed 03 November 2014]
- Bernatsky S, Hudson M, Panopalis P, et al. The cost of systemic sclerosis. Arthritis Rheum 2009;61(1):119-23
- Panopalis P, Petri M, Manzi S, et al. The systemic lupus erythematosus tri-nation study: cumulative indirect costs Arthritis Rheum. 2007;57(1):64-70